The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year 0 0 MAXIMUS Infomundi's AI Listen Turning complex stories into clear, actionable insights. Complete the captcha to unlock Maximus Chat with Maximus Ask anything about this story
Coinbase CEO's anti-aging startup NewLimit is raising $435 million, tripling its valuation
The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year
Turning complex stories into clear, actionable insights.
Complete the captcha to unlock Maximus
Share this article:
Quartz
Brought to you by InfomundiLike this publisher? Add them to your personal feed and combine publishers, tags, and categories to build a custom news page just for you.
Related coverage
Tags
CEO anti-aging Coinbase CEO Francisco biotech San Francisco South SanGlobal Coverage
This story is being covered by 0 countries
Trending